United Rentals Unusual Options Activity For June 03
Whales with a lot of money to spend have taken a noticeably bearish stance on United Rentals. Looking…
Marvell Tech’s Options Frenzy: What You Need to Know
Whales with a lot of money to spend have taken a noticeably bullish stance on Marvell Tech. Looking…
Decoding Verizon Communications’s Options Activity: What’s the Big Picture?
Whales with a lot of money to spend have taken a noticeably bearish stance on Verizon Communications. Looking…
Jim Cramer Sounds Alarm Bell, Advises Investors To Take Profits As GameStop, AMC Shares Soar: ‘There’s Nothing There’
Jim Cramer suggested that those piling into the meme names to try to catch a piece of the rally are likely going to get burned.
Goldman Sachs, JPMorgan, And Wells Fargo Lead Bank Stocks Surge As Investors Bet On Soft Landing
Bank stocks have had a successful year with potential for more growth if economic stability is maintained. BofA predicts positive sector performance in US elections and potential regulatory changes.
What the Options Market Tells Us About Li Auto
Investors with a lot of money to spend have taken a bearish stance on Li Auto (NASDAQ:LI). And…
Salesforce Options Trading: A Deep Dive into Market Sentiment
Deep-pocketed investors have adopted a bullish approach towards Salesforce (NYSE:CRM), and it’s something market players shouldn’t ignore. Our…
Bitcoin’s Macro Outlook This Week: ‘The Trend Is Our Friend,’ Says Analyst
Crypto and macro analyst Ted provided a comprehensive market outlook, highlighting key economic trends and their potential impact on Bitcoin (CRYPTO: BTC) and Ethereum (CRY
Microbot Medical Announces $2.35M Registered Direct Offering Of 1,566,669 Shares Of Common Stock At A Price Of $1.50 Per Share
Microbot Medical Inc. (NASDAQ:MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 1,566,669 shares of the Company's common stock at a purchase price of $1.50 per share of
Why Is Agios Pharmaceuticals Stock Trading Higher On Monday?
Agios Pharmaceuticals shares rose after it announced its Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia achieved the primary endpoint of transfusion reduction response.